

## **Approving the distribution of the net profit for the year 2023, setting the gross dividend per share and establishing the payment term**

The distribution of the net profit related to the financial year 2023, reported on the basis of the audited individual financial statements, is based on the following legal requirements:

- G.D. no. 64/2001 regarding the distribution of profit to enterprises, corporations and commercial companies which are majority or completely state-owned, as well as to autonomous administrations, with subsequent amendments and supplements;
- The law on commercial companies no. 31/1990, with subsequent amendments and supplements;
- The law no. 227/2015 regarding the Fiscal Code, with subsequent amendments and supplements;
- The law no. 24/2017 regarding the issuers of financial instruments and market operations;
- The resolution of the Ordinary General Meeting of Shareholders no. 1 of 16.02.2023, regarding the approval of the income and expenditure budget for the year 2023 of Antibiotice S.A. Iasi.

The net profit of the financial year 2023, reported on the basis of the audited annual financial statements, amounts to 81,088,596 lei distributed according to legal requirements:

Destination	Amount (lei)
- the legal reserve, constituted at the maximum level from the profit of the previous years	0
- other profit reserves	19,233,858
- dividends of which:	30,927,369
• dividends due to the Majority Shareholder	16,396,848
• dividends due to other legal entities and individuals	14,530,521
- the company's own sources of financing	30,927,369
The net profit for the year 2023, reported based on the audited annual financial statements	81,088,596

Other reserves in the amount of 19,233,858 lei are established according to art. 22, paragraph 5 of Law no. 227/2015 on the Fiscal Code with subsequent amendments and supplements "The amount of profit for which the profit tax exemption was granted, ..., is distributed at the end of the financial year or during the following year, with priority for the establishment of reserves, up to the accounting profit recorded at the end of the financial year", from which:

- 16,611,471 lei represents tax benefits for the profit invested in technological equipment, electronic computers and peripheral equipment, ..., as well as in computer

programs produced and/or purchased according to art. 22, paragraph 5 of Law no. 227/2015 regarding the Fiscal Code;

- 2,622,387 lei represent fiscal facilities for research and development activities according to art. 20 of Law no. 227/2015 regarding the Fiscal Code.

The amount of 30,927,369 lei from the net profit related to the year 2023 is distributed to dividends proportional to the participation rate in the share capital as follows:

- |   |                |
|---|----------------|
| – Ministry of Health (53.0173 %)                  | 16,396,848 lei |
| – Other legal entities and individuals (46.9827%) | 14,530,521 lei |

The amount of 30,927,369 lei represents the company's own source of financing according to the legal provisions.

The value of the gross dividend per share of 0.04606825 lei/share was calculated by corroborating the value of 30,927,369 lei of the dividends due to the shareholders, according to the proposal for distribution of the net result related to the year 2023, with the number of shares of 671,338,040 components of the subscribed and paid-up capital.

The payment of the dividends for the year 2023 will be performed starting with 11.10.2024, according to the legal provisions in force. We note that the dividend payment value is calculated by rounding to two decimal places.

The dividend tax will be calculated and withheld by Antibiotice S.A. in accordance with the requirements of Law no. 227/2015 regarding the Fiscal Code.

**GENERAL DIRECTOR**  
Ec. Ioan NANI

**FINANCIAL DIRECTOR**  
Ec. Paula COMAN